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Introduction. Rheumatoid arthritis patients under treatment with anti-TNF-α are at a high risk of 
developing active tuberculosis, and therefore, screening for latent tuberculosis infection is recommended 
before anti-TNF-α therapy.
Objective. To compare the tuberculin test and IFNγ production induced by culture filtrate proteins 
(CFPs) and Mycobacterium tuberculosis-specific CFP-10 antigens in rheumatoid arthritis patients.
Materials and methods. An analytic transversal study was conducted in rheumatoid arthritis patients 
treated at Hospital Universitario San Vicente Fundación between January and December 2007. IFNγ 
production in response to CFPs and CFP-10 was measured in the supernatants of whole blood cultures 
and evaluated for correlations with tuberculin reactivity. The degree of concordance between both tests 
was also established.
Results. Forty-five patients were included, of which 14 (31.1%) had a tuberculin reaction of ≥10 mm 
of induration, 9 (20%) produced IFNγ in response to CFP-10, and 7 were positive for both tests. The 
correlation between tests was r=0.53 (IC 95%:0.28-0.72), and the global concordance between tests was 
80%, with a Kappa coefficient of 0.48 (IC95%:0.20-0.76).
Conclusions. Only two tuberculin (-)/CFP-10+ “anergic” patients were observed. By contrast, six 
tuberculin +/CFP-10(-) “tuberculin false-positive” patients were observed. These data suggest that the 
tuberculin test is not an appropriate tool for determining the need for tuberculosis prophylaxis.
Keywords: Arthritis, rheumatoid; latent tuberculosis; tuberculin test; interferon gamma release assay; 
interferon-gamma; tumor necrosis factor-alpha/antagonists and inhibitors.
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Correlación de la respuesta a antígenos de Mycobacterium tuberculosis y la prueba cutánea de 
tuberculina en pacientes con artritis reumatoide
Introducción. Los pacientes con artritis reumatoide bajo tratamiento con anti-TNFα están en alto 
riesgo de desarrollar tuberculosis activa, por lo cual se recomienda hacer la tamización para infección 
latente de tuberculosis, antes de iniciar el tratamiento.
Objetivo. Comparar la prueba de tuberculina y la producción de IFNγ inducida por antígenos CFP 
(Culture Filtrate Protein) y antígenos específicos de Mycobacterium tuberculosis (CFP-10) para el 
diagnóstico de infección latente de tuberculosis en pacientes con artritis reumatoide.
Materiales y métodos. Se llevó a cabo un estudio transversal analítico en pacientes con artritis 
reumatoide atendidos en el Hospital Universitario San Vicente Fundación, entre enero y diciembre 
de 2007, a los cuales se les determinó la producción de IFNγ en respuesta a CFP y CFP-10 en 
sobrenadantes de cultivos de sangre total, y se correlacionó con la reacción en la prueba de tuberculina. 
Además, se estableció el grado de concordancia entre ambas pruebas.
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Resultados. Se incluyeron 45 pacientes, de los cuales, 14 (31,1 %) tuvieron un diámetro de induración 
≥10 mm (tuberculina positiva), nueve (20 %) produjeron IFNγ en respuesta a CFP-10, y siete fueron 
positivos para ambas pruebas. La correlación entre las pruebas fue de r=0,53 (IC95%: 0,28-0,72) y la 
concordancia global entre pruebas fue de 80 %, con un coeficiente kappa de 0,48 (IC95%: 0,20-0,76).
Conclusiones. Solo se observaron dos pacientes con tuberculina positiva y CFP-10 positivo “anérgicos” 
y se encontraron seis pacientes con tuberculina positiva y CFP-10 negativa “falsos positivos para 
tuberculina”, lo cual sugiere que la prueba de la tuberculina no es la más adecuada para indicar profilaxis 
para tuberculosis.
Palabras clave: artritis reumatoide, tuberculosis latente, prueba de tuberculina, interferón gamma, 
factor de necrosis tumoral alfa/antagonistas e inhibidores.
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Rheumatoid arthritis (RA) is a chronic inflammatory 
disorder that primarily attacks synovial joints, and it 
affects approximately 1% of the world’s population 
(1). Rheumatoid arthritis causes pain, impairs 
functional capability, and reduces patient quality of 
life. Current treatments with anti-TNF-α monoclonal 
antibody or soluble TNF-α receptor abrogate joint 
inflammation and damage (2,3).
Many studies have suggested that the clinical use of 
anti-TNF-α agents for the treatment of rheumatoid 
arthritis in humans increases the risk of tuberculosis 
reactivation (4-6). Therefore, screening for latent 
infection by Mycobacterium tuberculosis (LTBI) 
is recommended for patients with rheumatoid 
arthritis before initiating anti-TNF-α therapy to 
avoid tuberculosis reactivation (7-9). Traditionally, 
the tuberculin skin test (TST) has been used to 
detect LTBI. However, the TST is not specific, 
and its interpretation is often difficult in individuals 
vaccinated with Mycobacterium bovis bacillus 
Calmette-Guérin (BCG) and in individuals who have 
been exposed to environmental mycobacteria (9). 
In addition, patients on immunosuppressive therapy 
and those who are HIV infected or have cancer have 
a diminished TST response (10). Furthermore, the 
cut-off value of the TST changes according to the 
tuberculosis prevalence, BCG coverage and non-
tuberculosis mycobacteria exposure (11,12).
IFNγ release assays (IGRAs), which measure the 
T-cell response to the Mycobacterium tuberculosis-
specific antigens ESAT-6 and CFP-10 (13-17), are 
new specific and sensitive alternatives for LTBI 
diagnosis. Therefore, the management guidelines 
for LTBI diagnosis in some countries are replacing 
the TST with IGRAs (14-16), although inconsistent 
results have been reported (11-14,16,18,19). Our 
aim was to compare the TST and IFNγ production 
induced by Mycobacterium tuberculosis (Mtb) CFP 
and Mtb-specific CFP-10 antigens in rheumatoid 
arthritis patients in Colombia, a country with an 
intermediate tuberculosis prevalence (20) and high 
BCG vaccination coverage (72.7%) (21).
Materials and methods
Patients
A transverse analytic study was conducted. The 
study included patients older than 18 years of 
age with rheumatoid arthritis who were diagnosed 
according to the criteria of the American College of 
Rheumatology (1987) (22) and had never received 
biological therapy. The patients were recruited at the 
Servicio de Reumatología, Hospital Universitario 
San Vicente Fundación, Medellín, Colombia, between 
January and December 2007. Patients diagnosed 
with diabetes, cancer, HIV infection, hepatic or 
renal disease, or active tuberculosis were excluded. 
The study was approved by the Ethics Committee 
of Instituto de Investigaciones Médicas, Facultad 
de Medicina, Universidad de Antioquia, and all 
participants signed a consent form.
Clinical evaluation
The clinical and therapeutic characteristics of 
the patients were collected during the medical 
examination and were registered on a questionnaire 
designed for the investigation. The results of routine 
laboratory tests were obtained from the clinical 
records.
Tuberculin skin test
Patients underwent skin testing by an intradermal 
injection of 0.1 ml of tuberculin (RT23, Statens 
Serum Institut, Copenhagen, Denmark) in the left 
forearm volar surface. All the indurations were 
measured after 72 hours using the ballpoint-pen 
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technique. The values were categorized considering 
a cut-off value >10 mm for a positive test.
Blood collection and cell culture
Before the TST, peripheral blood samples were 
obtained by venipuncture and collected into EDTA 
tubes. Whole blood cultures were performed as 
follows: 20 µl of whole blood was diluted in 180 µl of 
RPMI-1640 (GIBCO, Grand Island, NY) containing 
Mtb antigens (CFP 10 µg/ml and CFP-10 5 µg/
ml; kindly provided by J. Belisle and K. Dobos, 
Colorado State University, Contract number: NIH, 
NIAID ND1-AI-40091, TB Vaccine Testing and 
Research Materials Contract) or medium alone. 
Cultures were incubated for seven days at 37°C 
in 5% CO2. The supernatants were collected and 
stored at -70°C (23).
IFN-γ measurement by enzyme-linked 
immunosorbent assay
The determination of IFNγ released into whole 
culture supernatant was performed by enzyme-
linked immunosorbent assay (ELISA) following the 
protocol recommended by the manufacturer (R&D 
systems, Minneapolis, MN). Briefly, ELISA plates 
(MaxiSorp, Nalge Nunc International, Rochester, 
NY) were incubated overnight at room temperature 
with 100 µl of diluted IFNγ capture antibody. The 
plates were then washed 3 times with 300 µl of 
wash buffer (0.05% Tween-20 in PBS, pH 7.4) and 
dried by tapping on absorbent paper. Blocking was 
performed by filling the wells with blocking buffer 
[PBS containing 1% bovine serum albumin, 5% 
sucrose and 0.05% NaN3] and incubating the plate 
for 2 h. After washing, samples and standards 
were prepared in diluent buffer [0.1% bovine serum 
albumin, 0.05 % Tween-20 in Tris-buffered saline pH 
7.3 (20 mM Trizma base, 150 mM NaCl)], and 100 µl 
of the supernatant dilutions was added to the wells 
and incubated µl of diluted biotinylated detection 
antibody was dispensed into each well, and the 
plates were incubated for 2 h at room temperature. 
The anti-IFNγ biotinylated antibody was diluted in 
2% heat-inactivated normal goat serum 2 h before 
use. The plates were then washed and 100 µl of 
a 1/200 dilution of horseradish peroxidase (HRP)-
streptavidin conjugate in Poly-HRP dilution buffer 
(Endogen, Woburn, MA) was added to each well 
before incubation for 20 min. The plates were 
washed, and 100 µl of substrate reagent was 
dispensed into each well and incubated at room 
temperature for 12 min in the dark. The reaction 
was stopped using 50 µl/well of stop solution 
(0.18 M H2SO4), and optical densities were read 
immediately at 450 nm and corrected at 490 nm 
(Bio-Tek Instruments, Kimpton, UK).
Statistical analyses
Absolute and relative frequencies were used to 
describe qualitative variables, and the median 
and interquartile range were used for quantitative 
variables. The normality of the distribution was 
evaluated using Shapiro-Wilk´s test. The amounts 
of IFNγ released in response to CFP and CFP-
10 were calculated by interpolation to non-linear 
regression standard curves. The cut-off value for 
IFNγ production levels was established at 22 pg/
mL, according to a previous report by our group 
(22). The values of the induration of the TST were 
evaluated for a correlation with the IFNγ released 
in response to CFP and CFP-10 by Spearman`s 
correlation coefficient, and the concordance between 
tests was evaluated by the global concordance and 
Kappa coefficient. Analyses were performed using 
GraphPad Prism version 5 (GraphPad Software, 
San Diego, California, USA).
Results
Clinical characteristics of the studied 
population 
During the study period, 45 patients were selected 
according to the eligibility criteria. The study 
included 42 women, and the median age was 45.5 
years (interquartile range, 41 to 55 years). A disease 
duration of less than 10 years was observed in 24 
patients (53.3%), and 40 patients (88.9%) had a 
BCG scar. Most patients had mild to moderate RA 
activity, which was evaluated with the DAS-28 (24) 
and acute phase proteins (APs) measured by the 
sedimentation rate and the C- reactive protein level 
(table 1). 
The most frequently used disease-modifying 
antirheumatic drug (DMARD) was methotrexate 
in 34 (75.6%) patients, while 39 (86.7%) patients 
were taking steroids with a previous year median 
accumulated dose of 1885 mg (1825 mg-2735 mg) 
(table 2).
Comparison of TST and IFNγ-based blood tests
As shown in figure 1, 29 patients (64.4%) had a 
TST induration of 0 mm, 14 patients (31.1%) had a 
TST induration ≥ 10 mm, and only 2 (4.4%) patients 
had a TST induration between 1 and 9 mm. 
The production of IFNγ induced by CFP stimuli was 
≥ 22 pg/ml in 18 (40%) patients, while only 9 (20%) 
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produced ≥ 22 pg/ml of IFNγ in response to CFP-
10. These 9 patients were considered positive for 
LTBI, given the high specificity of CFP-10 for TB 
infection.
The distribution of the results obtained based on 
the vaccination status is shown in figure 2. Because 
the majority of patients had been vaccinated with 
Table 1. Demographic and clinical characteristics of the rheumatoid 
arthritis patients
 n (%)
Gender, female   42 (93.3)
Cigarette smoking, negative  38 (84.4)
BCG scar, positive  40 (88.9)
Disease duration < 10 years 24 (53.3)
  11-20 years 16 (35.5) 
  > 21 years 5 (11.1)
Rheumatoid Factor,   23 (65.7)
Positive (n=35)  
   Median
   (Interquartile range)
Age (years)   45 (41-55)
Body mass index  23 (21-26)
Erythrocyte sedimentation rate 
(mm/h) (n=41)   30 (7-39)
C reactive protein (mg/dl)   (n=34)  0.6 (0.2-3.0)
HAQ (Health assessment questionnaire) 0.6 (0.1-1.9)
DAS28 (Disease activity score-28)  3.9 (2.5-5.9)
Pain VAS (n=43) (Visual analogue scale) 44 (10-78)
Global VAS (n=43)  50 (11-85)
Table 2. Treatment of rheumatoid arthritis patients
Variables n (%)
Prednisolone 39 (86.7)
Prednisolone accumulated dose
(Median + interquartile range) 1885 mg (1825-2735 mg)
Chloroquine 26 (57.8)
Methotrexate 34 (75.6)
Leflunomide 14 (31.1)
Azathioprine 0 (0)
Figure 2. Analysis of the response of rheumatoid arthritis patients by BCG vaccination status. (A) Distribution of erythema diameter 
following the TST (mean ± SE) in rheumatoid arthritis patients in the BCG+ and BCG- groups (A). Geometric mean of IFNγ production 
after CFP-10 stimulation in the BCG+ and BCG- groups (B). The horizontal dotted line indicates the cut-off value for IFNγ production 
levels.
BCG, it was not possible to determine whether 
vaccination influenced the TST and IGRA results. 
Correlation between the TST and IGRAs in 
rheumatoid arthritis patients
Because the diagnostic value of the TST test 
has been questioned due to its low specificity in 
individuals vaccinated with Mycobacterium bovis 
bacillus Calmette-Guérin (BCG) and individuals 
exposed to environmental mycobacteria, we 
evaluated the correlation between this test and 
the IFNγ response to CFP and CFP-10. Because 
the data did not follow a normal distribution, 
Spearman´s correlation test was used. The TST 
correlated with the CFP- and CFP-10-induced 
IFNγ levels (Spearman r=0.73 95% CI 0.54-0.84, 
p<0.0001, and Spearman r=0.53 95%CI 0.28-
0.72, p<0.001, respectively) (figure 3). Six patients 
Figure 1. Distribution of tuberculin skin test (TST) induration 
size in patients with rheumatoid arthritis. For the analysis, the 
reactivity of the rheumatoid arthritis patients was divided into 7 
groups, including a negative (0 mm) group. (n=45)
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(13.3%) presented a TST induration greater than or 
equal to 10 mm and were CFP10 negative (< 22 pg/
ml IFNγ) and were thus considered false-positive 
TST patients. In contrast, only two patients (4.4%) 
had a TST induration < 10 mm and were CFP10 
positive (> 22 pg/ml IFNγ) and were considered 
“anergic”. The global agreement between CFP10 
and the TST was 80%, with an expected agreement 
of 61% and a coefficient κ= 0.48 (CI 95% 0.20-
0.76). The agreement between the TST and CFP 
was 82%, with an expected agreement of 54% and 
a coefficient κ= 0.61 (CI 95% 0.38-0.85).
Discussion
TNF-α plays a major role in the immune response 
against Mtb, and the increase in the TB case 
number associated with anti-TNF-α therapy has 
increased its importance (25). The diagnosis and 
chemoprophylaxis of LTBI is an important issue 
to consider before initiating anti-TNF therapy in 
patients with rheumatologic diseases such as 
rheumatoid arthritis (18,26,27).
The TST has traditionally been used to detect 
LTBI; however, it is not a very specific diagnostic 
tool (28,29). This may be explained by the possible 
effects of BCG vaccination (30-32) and the presence 
of environmental mycobacteria (33), which can 
increase the incidence of false-positive results in 
countries such as Colombia, where vaccination 
is widely and routinely performed. The number of 
patients without BCG in our study was very low 
and did not allow us to determine whether previous 
vaccination influenced the TST response.
Furthermore, in our study, six patients had a TST 
induration >10 mm and were CFP10 negative, 
and due to the higher specificity of the IGRAs, we 
interpreted these patients as having false-positive 
TST results. Additionally, as in other previously 
reported studies of autoimmune diseases such 
as rheumatoid arthritis and lupus in countries with 
high vaccination indexes, our study demonstrated 
a poor concordance between the TST and IGRAs 
(16,34,35). Given the high specificity of IGRAs, 
these assays should be used as confirmatory 
tests of infection by Mtb, particularly in rheumatoid 
arthritis patients for whom TST screening is positive, 
to avoid false-positive diagnoses and allow an 
accurate decision regarding whether to initiate 
prophylaxis therapy with isoniazid or rifampin.
The effect of immunosuppressive therapy on the 
TST response should also be considered. The 
accuracy and reliability of the TST are significantly 
affected by immunosuppressive therapy and by 
cellular and humoral immune system disturbances 
related to RA (13,14,36). In this study, most 
patients, despite receiving this type of therapy, 
responded to the TST, and some patients even 
presented high TST induration values. Therefore, 
the tuberculin anergy previously described in 
rheumatoid arthritis patients in other reports (36-
38) was not observed in our study. 
Figure 3. Correlation between the results of the tuberculin skin test (TST) and interferon (IFN)-γ production following the stimulation 
of whole blood cells with CFP and CFP-10 proteins in vitro. Secreted IFN-γ was measured by enzyme-linked immunosorbent assay 
(ELISA). The vertical dotted line indicates the 10 mm TST cut-off. The horizontal dotted line indicates the cut-off value for IFN-γ 
production levels (22 pg/ml). Spearman`s correlation coefficient and the concordance between tests were evaluated by the global 
concordance and Kappa coefficient. The two-tailed p value was *** p<0.0001.
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The distribution of TST reactivity in our patient 
cohort showed that 31.1% of patients had a TST 
induration > 10 mm, whereas only two patients 
had indurations of 5-9 mm. This finding suggests 
that a cut-off for TST reactivity of 10 mm may be 
more appropriate for our patients than the 5 mm 
cut-off suggested by other studies (39) and the 
management guidelines of other countries with 
different TB epidemiologies (7,8).
The significance of TST reactivity is very 
controversial. Although our sample was small, in 
contrast to other studies (39), the findings suggest 
that TST false-positive results are more likely to 
be observed in rheumatoid arthritis patients than 
“anergy” and that TST-positive results for LTBI 
screening in rheumatoid arthritis patients could 
lead to an overestimation of the proportion of LTBI 
individuals and should not be used to determine 
the need for chemoprophylaxis therapy. The main 
limitation of this study is the small sample size 
because it was a convenience sample. Therefore, 
the results must be carefully interpreted in this 
context. In conclusion, IGRAs are an important 
second step in the diagnosis of true-positive 
patients after screening with the TST (40).
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